Carregant...
Discovery of IDO1 inhibitors: from bench to bedside
Small molecule inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging at the vanguard of experimental agents in oncology. Here pioneers of this new drug class provide a bench-to-bedside review on preclinical validation of IDO1 as a cancer therapeutic target and on the discovery and developm...
Guardat en:
| Publicat a: | Cancer Res |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6021761/ https://ncbi.nlm.nih.gov/pubmed/29247038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-2285 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|